Full text is available at the source.
Abstract
Semaglutide significantly reduced body weight, regional adiposity, and insulin resistance over 32 weeks of active treatment.
- HIV-associated lipohypertrophy involves excess fat accumulation in the central and visceral areas.
- Increased cardiometabolic risk is observed among people living with HIV.
- The long-term effects of semaglutide after stopping treatment remain unclear.
Simplified